Related references
Note: Only part of the references are listed.Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL
Kristina Mueller et al.
BLOOD (2022)
NK Cells in the Tumor Microenvironment as New Potential Players Mediating Chemotherapy Effects in Metastatic Melanoma
Cinzia Garofalo et al.
FRONTIERS IN ONCOLOGY (2021)
Inter-cellular CRISPR screens reveal regulators of cancer cell phagocytosis
Roarke A. Kamber et al.
NATURE (2021)
DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma
Priya Choudhry et al.
LEUKEMIA (2020)
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study
Gilles Salles et al.
LANCET ONCOLOGY (2020)
Bcl-2/Bcl-xL inhibitor navitoclax increases the antitumor effect of Chk1 inhibitor prexasertib by inducing apoptosis in pancreatic cancer cells via inhibition of Bcl-xL but not Bcl-2
Yoshihito Morimoto et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2020)
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children
Veronique Minard-Colin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Venetoclax causes metabolic reprogramming independent of BCL-2 inhibition
Alba Roca-Portoles et al.
CELL DEATH & DISEASE (2020)
Pre-sensitization of Malignant B Cells Through Venetoclax Significantly Improves the Cytotoxic Efficacy of CD19.CAR-T Cells
Mingya Yang et al.
FRONTIERS IN IMMUNOLOGY (2020)
Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times
Christian Bailly et al.
NAR CANCER (2020)
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
T. D. Shanafelt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Phagocytosis checkpoints as new targets for cancer immunotherapy
Mingye Feng et al.
NATURE REVIEWS CANCER (2019)
Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas
Lan V. Pham et al.
CLINICAL CANCER RESEARCH (2018)
Autologous T-cell activation fosters ABT-199 resistance in chronic lymphocytic leukemia: rationale for a combined therapy with SYK inhibitors and anti-CD20 monoclonal antibodies
Esteban Enrique Elias et al.
HAEMATOLOGICA (2018)
Daratumumab for relapsed/refractory Philadelphia-positive acute lymphoblastic leukemia
Chezi Ganzel et al.
HAEMATOLOGICA (2018)
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
J. F. Seymour et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Autologous T-cell activation fosters ABT-199 resistance in chronic lymphocytic leukemia: rationale for a combined therapy with SYK inhibitors and anti-CD20 monoclonal antibodies
Esteban Enrique Elias et al.
HAEMATOLOGICA (2018)
Daratumumab for relapsed/refractory Philadelphia-positive acute lymphoblastic leukemia
Chezi Ganzel et al.
HAEMATOLOGICA (2018)
Perspectives of Fc engineered antibodies in CD19 targeting immunotherapies in pediatric B-cell precursor acute lymphoblastic leukemia
Christian Kellner et al.
ONCOIMMUNOLOGY (2018)
A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia
Haley E. Ramsey et al.
CANCER DISCOVERY (2018)
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma
Ranjana Advani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Hematologic Tumor Cell Resistance to the BCL-2 Inhibitor Venetoclax: A Product of Its Microenvironment?
Joel D. Leverson et al.
FRONTIERS IN ONCOLOGY (2018)
First Evidence of Restoration of T and NK Cell Compartment after Venetoclax Treatment
Iris de Weerdt et al.
BLOOD (2018)
Combination Treatment with 5F9 and Azacitidine Enhances Phagocytic Elimination of Acute Myeloid Leukemia
Dongdong Feng et al.
BLOOD (2018)
Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression
Timothy L. Lochmann et al.
CLINICAL CANCER RESEARCH (2018)
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Matthew S. Davids et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study
John F. Seymour et al.
LANCET ONCOLOGY (2017)
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Found in Translation : How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax
Joel D. Leverson et al.
CANCER DISCOVERY (2017)
The Development and Current Use of BCL-2 Inhibitors for the Treatment of Chronic Lymphocytic Leukemia
Benjamin L. Lampson et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2017)
New Strategies Using Antibody Combinations to increase Cancer Treatment effectiveness
Isabel Corraliza-Gorjon et al.
FRONTIERS IN IMMUNOLOGY (2017)
An Fc-engineered CD19 antibody eradicates MRD in patient-derived MLL-rearranged acute lymphoblastic leukemia xenografts
Denis M. Schewe et al.
BLOOD (2017)
Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
Arend von Stackelberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial
Vincent Ribrag et al.
LANCET (2016)
Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
Marina Konopleva et al.
CANCER DISCOVERY (2016)
Clinical and pathological features of Burkitt lymphoma showing expression of BCL2-an analysis including gene expression in formalin-fixed paraffin-embedded tissue
Neus Masque-Soler et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Effects of p38α/β inhibition on acute lymphoblastic leukemia proliferation and survival in vivo
A. Alsadeq et al.
LEUKEMIA (2015)
Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options
Ute Fischer et al.
NATURE GENETICS (2015)
Sensitizing Protective Tumor Microenvironments to Antibody-Mediated Therapy
Christian P. Pallasch et al.
CELL (2014)
Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer
L. Bracci et al.
CELL DEATH AND DIFFERENTIATION (2014)
Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer
Saskia Meyer et al.
MABS (2014)
Lysophospholipids secreted by splenic macrophages induce chemotherapy resistance via interference with the DNA damage response
Julia M. Houthuijzen et al.
NATURE COMMUNICATIONS (2014)
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Andrew J. Souers et al.
NATURE MEDICINE (2013)
Mimicking an Induced Self Phenotype by Coating Lymphomas with the NKp30 Ligand B7-H6 Promotes NK Cell Cytotoxicity
Christian Kellner et al.
JOURNAL OF IMMUNOLOGY (2012)
Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC
Roland Repp et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2011)
Phase II Window Study on Rituximab in Newly Diagnosed Pediatric Mature B-Cell Non-Hodgkin's Lymphoma and Burkitt Leukemia
Andrea Meinhardt et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Broad-spectrum caspase inhibitors: from myth to reality?
D. Chauvier et al.
CELL DEATH AND DIFFERENTIATION (2007)
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma
Thomas M. Habermann et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
The macrophage and the apoptotic cell: an innate immune interaction viewed simplistically?
CD Gregory et al.
IMMUNOLOGY (2004)
Increased sensitivity of early apoptotic cells to complement-mediated lysis
G Attali et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2004)
Share Paper
